PAL – Morgans rates the stock as Add

The first half underlying net loss for Palla Pharma was below Morgans expectations. The result was impacted by a major UK customer manufacturing license loss and the early jettison of a non-opiate contract manufacturing organisation (CMO) contract. Additionally, the supply chain was affected by covid-19 disruptions, explains the broker.

Read More